Back

Deficiency in POLE exonuclease causes synthetic lethality in highly aneuploid cancer cells

Kim, E. J.; Chibly, A.; Dorighi, K.; Kamm, J.; Juszkiewicz, S.; Cabrera, K.; Jin, D.; Reja, R.; Wang, Y.; Nakagawa, R.; Shi, M.; Liang, Y.; Dey, A.; Sokol, E. S.; Gendreau, S.; He, M.

2025-07-30 cancer biology
10.1101/2025.07.16.665237 bioRxiv
Show abstract

Aneuploidy is a hallmark of cancer and is associated with drug resistance and poor clinical outcomes across diverse cancer types. However, no therapies have been clinically established to target highly aneuploid tumors. By analyzing a real-world dataset comprising nearly half a million tumor samples subjected to comprehensive genomic profiling, we identified a striking mutual exclusivity between POLE exonuclease domain mutations and high aneuploidy burden. This observation was independently validated using data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE). Probabilistic modeling revealed that the elevated quantity and unique spectrum of mutations induced by POLE exonuclease deficiency increase the likelihood of inactivating essential genes on chromosome arms harboring losses, leading to a synthetic lethal phenotype in highly aneuploid cells. Functional experiments demonstrated that POLE exonuclease activity is essential for the viability of highly aneuploid cancer cell lines but is dispensable in diploid cells. These findings suggest that selective inhibition of POLE exonuclease may represent a promising therapeutic strategy for targeting highly aneuploid tumors.

Published in Cancer Research (predicted rank #7) · training set

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Genome Medicine
○ 183 papers in training set
Top 0.2%
9.5%
Similar papers in this journal
2
Genome Biology
○ 637 papers in training set
Top 2%
6.5%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 24%
6.5%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 23%
5.4%
Similar papers in this journal
5
Cancers
○ 213 papers in training set
Top 1%
5.0%
Similar papers in this journal
6
Nucleic Acids Research
◐ 1281 papers in training set
Top 4%
4.7%
Cancer Research · published here
● 130 papers in training set
Top 0.8%
4.7%
8
Cancer Research Communications
● 51 papers in training set
Top 0.2%
3.9%
9
PLOS Genetics
● 862 papers in training set
Top 3%
3.9%
50% of probability mass above
10
NAR Cancer
◐ 37 papers in training set
Top 0.1%
3.3%
11
Scientific Reports
○ 3612 papers in training set
Top 34%
3.1%
12
Molecular Cancer Research
● 49 papers in training set
Top 0.4%
3.0%
13
Oncogene
○ 85 papers in training set
Top 0.7%
2.7%
14
npj Precision Oncology
○ 53 papers in training set
Top 0.6%
2.4%
15
Cell Reports
○ 1498 papers in training set
Top 17%
2.1%
16
Cancer Letters
○ 35 papers in training set
Top 0.5%
1.9%
17
Science Advances
● 1243 papers in training set
Top 21%
1.6%
18
Communications Biology
○ 993 papers in training set
Top 16%
1.6%
19
Molecular Oncology
○ 55 papers in training set
Top 0.8%
1.4%
20
Cancer Discovery
● 66 papers in training set
Top 1%
1.3%
21
PLOS ONE
● 5266 papers in training set
Top 54%
1.1%
22
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 36%
1.1%
23
Cell Genomics
○ 172 papers in training set
Top 4%
1.1%
24
Clinical Cancer Research
● 64 papers in training set
Top 2%
1.1%
25
Genome Research
● 468 papers in training set
Top 5%
1.0%
26
Genomics, Proteomics & Bioinformatics
188 papers in training set
Top 2%
1.0%
27
Genes & Development
● 90 papers in training set
Top 2%
0.9%
28
Modern Pathology
○ 22 papers in training set
Top 0.4%
0.8%
29
Open Biology
● 106 papers in training set
Top 2%
0.8%
30
iScience
○ 1154 papers in training set
Top 38%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.